Sex: F
Vaccine: HEP
Symptoms: Peritonsillar abscess
Clinical narrative: This case was reported in a literature article and described the occurrence of peritonsillar abscess in a 46-year-old female subject who received Hepatitis B vaccine. Concomitant products included Hepatitis B vaccine and Hepatitis B vaccine. On 1st August 2006, 175 days after receiving Hepatitis B vaccine, the subject developed peritonsillar abscess. Serious criteria included GSK medically significant. Additional event(s) included lichen planus on 1st August 2006, mouth ulcer on 1st August 2006 and lichenoid keratosis on 1st August 2006. The subject was treated with Antibiotics (Brand Names Not Known). The outcome of peritonsillar abscess was unknown. The outcome(s) of the additional event(s) included lichen planus (unknown), mouth ulcer (unknown) and lichenoid keratosis (unknown). The investigator considered the peritonsillar abscess, lichen planus, mouth ulcer and lichenoid keratosis to be possibly related to Hepatitis B vaccine. Relevant Tests: The computed tomography (CT) to R10 peritonsillar abscess was negative. Ear, nose, and throat (ENT) specialist gave diagnosis of erosive lichen planus. The patient had tissue biopsy. Diagnostic results (unless otherwise stated, normal values were not provided): On 1st August 2006, Computerised tomogram result was see text unknown. Additional information was provided. This case was reported in a literature article and described the occurrence of lichenoid keratosis, mouth ulceration, peritonsillar abscess; oral lichen planus in a 46-year-old female patient who was vaccinated with ENGERIX-B (GlaxoSmithKline). The patient was part of the study that aimed to characterize and review cases of lichen planus (LP) and lichenoid drug eruption (LDE) following vaccination by analysing the Vaccine Adverse Event Reporting System (VAERS) database. On unspecified dates, the patient received 2 doses of unspecified hepatitis B virus vaccine. The patient's VAERS ID is 271936. No information on patient's medical or family history or concurrent condition or concomitant medication was provided. On 07 February 2006, the patient had received 3rd dose of ENGERIX-B (lot no AHBVB300AA) (administration site unspecified) intramuscularly. Age of vaccination was not provided. On 1 August 2006, 175 days after vaccination, the patient developed ulcerative lesions in her mouth. The patient was treated for peritonsillar abscess with antibiotics. No improvement occurred. The computed tomography (CT) to R10 peritonsillar abscess was negative. Ear, nose, and throat (ENT) specialist gave diagnosis of erosive lichen planus. The patient had tissue biopsy. Treatment was unknown. The outcome of the event was not reported. The author considered the events of lichenoid keratosis, mouth ulceration, peritonsillar abscess; oral lichen planus possibly related to ENGERIX-B.  The authors concluded, "Lichen planus and LDE can occur, albeit rarely, after vaccination, especially following hepatitis B vaccination. When middle-aged adults present to the clinic with LP or LDE, it is important to inquire about recent vaccination history in addition to a detailed medication history." This is 1 of the 9 valid cases in the same literature article.